Table 2 Demographic information and clinical variables at time of pre-test evaluation.

From: Multimedia-based hormone therapy information program for patients with prostate cancer: the result of a randomized pilot study

Variable

Entire sample (N = 76)

Diagnosed within 2 years (n = 48)

MIG (n = 36)

CG (n = 40)

χ2/t

MIG (n = 28)

CG (n = 20)

χ2/t

n (%)

[Mean ± SD]

n (%)

[Mean ± SD]

n (%)

[Mean ± SD]

n (%)

[Mean ± SD]

Age (years)

[73.22 ± 7.54]

[76.83 ± 8.33]

1.97

[73.75 ± 7.52]

[77.35 ± 9.66]

1.45

Educational level

  

0.89

  

0.20

 < Elementary school

15 (41.7)

21 (52.5)

 

13 (45.4)

8 (40.0)

 

 ≥ Junior high school

21 (58.3)

19 (47.5)

 

15 (53.6)

12 (60.0)

 

Marital status

  

a

  

a

 Married/cohabitating

30 (83.3)

36 (90.0)

 

22 (78.6)

19 (95.0)

 

 Divorced/widowed

6 (16.7)

4 (10.0)

 

6 (21.4)

1 (5.0)

 

Religious beliefs

  

1.26

  

a

 No

8 (22.2)

5 (12.5)

 

8 (28.6)

3 (15.0)

 

 Yes

28 (77.8)

35 (87.5)

 

20 (71.4)

17 (85.0)

 

Occupational status

  

6.12*

  

a**

 No

27 (75.0)

38 (95.0)

 

20 (71.4)

20 (100.0)

 

 Yes

9 (25.0)

2 (5.0)

 

8 (28.6)

0 (0.0)

 

Annual household income

  

4.11*

  

a

 < NT$500,000

30 (83.3)

25 (62.5)

 

23 (82.1)

16 (80.0)

 

 ≥ NT$500,000

6 (16.7)

15 (37.5)

 

5 (17.9)

4 (20.0)

 

Residential status

  

3.28

  

4.61

 Other residential status

9 (25.0)

6 (15.0)

 

9 (32.1)

2 (10.0)

 

 Live with partner only

5 (13.9)

12 (30.0)

 

5 (17.9)

8 (40.0)

 

 Live with partner and children with/without grandchildren

22 (61.1)

22 (55.0)

 

14 (50.0)

10 (50.0)

 

Body mass index

  

0.65

  

0.29

 18.5–24 (Normal)

13 (36.1)

11 (27.5)

 

9 (32.1)

5 (25.0)

 

 < 18.5 (Abnormal)

23 (63.9)

29 (72.5)

 

19 (67.9)

15 (75.0)

 

Perceived health status

[70.17 ± 11.66]

[71.88 ± 14.84]

0.55

[68.79 ± 12.27]

[68.50 ± 14.70]

− 0.07

Time since diagnosis (months)

[16.34 ± 22.15]

[47.58 ± 51.44]

3.50**

[6.66 ± 6.50]

[9.35 ± 8.10]

1.27

Recent concentration of serum PSA

[84.18 ± 245.39]

[23.49 ± 73.78]

1.43

[108.08 ± 274.58]

[24.17 ± 44.81]

− 1.59

Cancer stage

  

0.28

  

0.01

 Stage I–III

8 (22.2)

11 (27.5)

 

8 (28.6)

6 (30.0)

 

 Stage IV

28 (77.8)

29 (72.5)

 

20 (71.4)

14 (70.0)

 

History of past illness

  

a

  

0.04

 No

5 (13.9)

4 (10.0)

 

5 (17.9)

4 (20.0)

 

 Yes

31 (86.1)

36 (90.0)

 

23 (82.1)

16 (80.0)

 

Types of hormone therapy

  

6.08

  

1.51

 Orchiectomy

0 (0.0)

2 (5.0)

 

0 (0.0)

1 (5.0)

 

 Medical castration (injection only)

16 (44.4)

17 (42.5)

 

15 (53.6)

11 (55.0)

 

 Medical castration (injection and oral)

20 (55.6)

17 (42.5)

 

13 (46.4)

8 (40.0)

 

 Orchiectomy + medical castration

0 (0.0)

4 (10.0)

 

0 (0.0)

0 (0.0)

 

Positive thinking

[67.17 ± 7.07]

[67.23 ± 7.42]

0.03

[66.36 ± 7.59]

[66.35 ± 7.53]

 < − 0.01

General QOL

[79.86 ± 13.95]

[79.18 ± 15.42]

− 0.20

[76.6.79 ± 12.82]

[78.50 ± 11.75]

0.47

Prostate cancer-specific QOL

[116.39 ± 18.44]

[115.00 ± 20.92]

− 0.31

[112.21 ± 17.36]

[113.55 ± 16.87]

0.27

Hormone symptoms and distress

[85.67 ± 14.48]

[84.66 ± 15.45]

− 0.29

[84.17 ± 14.83]

[86.82 ± 12.87]

0.64

Social support

[34.69 ± 8.20]

[35.43 ± 9.56]

0.36

[34.50 ± 7.97]

[36.10 ± 8.04]

0.68

Self-efficacy

[29.44 ± 5.84]

[29.90 ± 5.32]

0.36

[28.21 ± 5.19]

[30.70 ± 5.08]

1.65

  1. aFisher’s exact test.
  2. *p < 0.05, **p < 0.01.
  3. CG control group, MIG multimedia information group, QOL quality of life, PSA prostate-specific antigen, SD standard deviation.